Cellectis S.A. Logo

Cellectis S.A. (ALCLS)

Euronext

Currency in EUR
2.87
-0.09 (-3.04%)

Closed

Aug 21, 2026

Day's Range

2.86
2.97

52 wk Range

2.03
4.84

Overview - ALCLS - Cellectis S.A.

Key Statistics

Valuation

Enterprise Value

104.73M

P/E (Trailing)

‪-4.11‬

P/E (Forward)

‪-1.81‬

PEG Ratio

‪-1.81‬

Price / Sales (TTM)

‪4.52‬

Price / Book

‪5.93‬

EV / EBITDA

‪-2.62‬

Profitability

Gross Margin

‪54.96%‬

Profit Margin

‪-102.33%‬

Operating Margin

‪-340.68%‬

Return on Assets

‪-11.66%‬

Return on Equity

‪-94.53%‬

Ownership

Shares Outstanding

100.69M

Float

46.78M

Held by Insiders

‪48.00%‬

Held by Institutions

‪10.42%‬

Price stats

Beta

‪2.75‬

50-Day Avg

‪2.58‬

200-Day Avg

‪3.24‬

Dividends

Payout Ratio

‪0.00%‬

Analyst Consensus

Buy

1 analysts

Market Cap - ALCLS - Cellectis S.A.

Peers - ALCLS - Cellectis S.A.

Peer Comparison

Compared with companies in Biotechnology listed on Euronext.

Profile Summary - ALCLS - Cellectis S.A.

About

Cellectis S.A. is a clinical-stage biopharmaceutical company specializing in the development of next-generation immunotherapies for cancer. With over 25 years of innovation, Cellectis leverages its proprietary TALEN® gene-editing technology to engineer chimeric antigen receptor (CAR) T-cells, creating "off-the-shelf"…

SectorHealthcare
IndustryBiotechnology
Employees216
Full company profile

The information on this page is provided for general informational purposes only and is not investment advice.

Market data provided by Twelve Data. Charting by TradingView.

Last updated:

Stocks news

Track Global Markets in Real Time with UA Finance

Download the app now and access live financial data, expert analysis, and trusted economic news to follow stocks, forex, gold, and cryptocurrencies with ease.